Isabelle Malet

Summary

Country: France

Publications

  1. ncbi request reprint Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients
    Isabelle Malet
    Laboratoire de Virologie bâtiment CERVI, Hopital Pitie Salpetriere, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Infect 54:367-74. 2007
  2. ncbi request reprint New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors
    Isabelle Malet
    Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d Epidémiologie et de Santé Publique, F 75013, Paris, France INSERM, UMR_S 1136, Institut Pierre Louis d Epidémiologie et de Santé Publique, F 75013, Paris, France AP HP, Laboratoire de Virologie, Hôpital Pité Salpêtrière, F 75013, Paris, France
    J Antimicrob Chemother 69:2118-22. 2014
  3. doi request reprint The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:2827-30. 2011
  4. doi request reprint Risk factors for raltegravir resistance development in clinical practice
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France
    J Antimicrob Chemother 67:2494-500. 2012
  5. doi request reprint Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
    Isabelle Malet
    UPMC Univ Paris 06, F 75005 Paris, France
    J Antimicrob Chemother 63:795-804. 2009
  6. doi request reprint Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:1481-3. 2011
  7. doi request reprint Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases
    Isabelle Malet
    UPMC Universite Paris 06, Paris, France
    J Med Virol 80:754-61. 2008
  8. pmc Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
    Isabelle Malet
    Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:1351-8. 2008
  9. doi request reprint Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists
    Cathia Soulie
    Universite Pierre et Marie Curie Paris 6, UMR S 943 Paris, F 75013, France
    J Antimicrob Chemother 65:749-51. 2010
  10. ncbi request reprint Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors
    Benedicte Roquebert
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 20:287-9. 2006

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients
    Isabelle Malet
    Laboratoire de Virologie bâtiment CERVI, Hopital Pitie Salpetriere, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Infect 54:367-74. 2007
    ..Moreover, we have evaluated associations between the Gag region sequence and the virological response to Protease Inhibitors (PI)...
  2. ncbi request reprint New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors
    Isabelle Malet
    Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d Epidémiologie et de Santé Publique, F 75013, Paris, France INSERM, UMR_S 1136, Institut Pierre Louis d Epidémiologie et de Santé Publique, F 75013, Paris, France AP HP, Laboratoire de Virologie, Hôpital Pité Salpêtrière, F 75013, Paris, France
    J Antimicrob Chemother 69:2118-22. 2014
    ....
  3. doi request reprint The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:2827-30. 2011
    ..The aim of this study was to explore resistance pathways preferably used by CRF02_AG viruses compared with subtype B...
  4. doi request reprint Risk factors for raltegravir resistance development in clinical practice
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France
    J Antimicrob Chemother 67:2494-500. 2012
    ..To investigate the best conditions of raltegravir use to avoid the selection of resistance mutations in the three main genetic pathways: 148, 155 and 143...
  5. doi request reprint Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
    Isabelle Malet
    UPMC Univ Paris 06, F 75005 Paris, France
    J Antimicrob Chemother 63:795-804. 2009
    ..The objective of this study was to characterize the dynamics of HIV-1 quasispecies variant populations in patients who failed to respond to raltegravir treatment...
  6. doi request reprint Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:1481-3. 2011
    ....
  7. doi request reprint Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases
    Isabelle Malet
    UPMC Universite Paris 06, Paris, France
    J Med Virol 80:754-61. 2008
    ..In conclusion, virological response to anti-integrase should be studied carefully, according to the subtype, in clinical trials...
  8. pmc Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
    Isabelle Malet
    Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:1351-8. 2008
    ..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
  9. doi request reprint Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists
    Cathia Soulie
    Universite Pierre et Marie Curie Paris 6, UMR S 943 Paris, F 75013, France
    J Antimicrob Chemother 65:749-51. 2010
    ..We aimed to analyse HIV-1 tropism using proviral DNA sequencing and the associated factors, in a group of patients on antiretroviral (ARV) treatment with an undetectable viral load in plasma...
  10. ncbi request reprint Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors
    Benedicte Roquebert
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 20:287-9. 2006
    ..These minor species, not detected by standard genotype, may influence PI susceptibility...
  11. ncbi request reprint Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes
    Almoustapha Issiaka Maiga
    Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 14:123-9. 2009
    ..The genetic barrier for IN inhibitor resistance was compared between HIV-1 subtype B and HIV-1 subtype CRF02_AG, which is highly prevalent in West Africa and becoming more frequent in developed countries...
  12. ncbi request reprint Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug
    Marc Wirden
    Department of Virology, AP HP, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    J Antimicrob Chemother 64:1087-90. 2009
    ..We determined whether raltegravir retains residual antiretroviral activity in vivo against viruses harbouring raltegravir mutations, and thus whether the drug can contribute to the subsequent regimen...
  13. doi request reprint Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease
    Sidonie Lambert-Niclot
    UPMC Univ Paris 06, EA 2387, F 75005, Paris, France
    J Antimicrob Chemother 62:905-8. 2008
    ..To search for genetic factors in the protease and gag regions (NC-p1/TFP-p6/p6pol) involved in selection of darunavir resistance mutations...
  14. ncbi request reprint Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients
    Isabelle Malet
    Laboratoire de Virologie, Universite Pierre et Marie Curie Paris 6, France
    AIDS 21:871-3. 2007
    ..Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M mutation. The impact of this mutation should be further addressed in vivo...
  15. doi request reprint E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
    Slim Fourati
    Université Pierre et Marie Curie Paris, Groupe Hospitalier Pitie Salpetriere, Laboratoire de Virologie, Paris, France
    AIDS 26:1619-24. 2012
    ..We show here that APOBEC3 proteins play a role in the emergence of these drug resistance mutations...
  16. doi request reprint E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations
    Slim Fourati
    Universite Pierre et Marie Curie, Paris, France
    Antiviral Res 93:167-74. 2012
    ..This process may play a role in the kinetics of appearance of drug resistance mutations under antiretroviral treatment...
  17. pmc Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes
    Almoustapha Issiaka Maiga
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC University Paris 06, INSERM U943, Paris, France
    Antimicrob Agents Chemother 54:728-33. 2010
    ..However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility...
  18. doi request reprint Length variability of telomeric repeat sequences of human herpesvirus 6 DNA
    Abla Achour
    Laboratoire de Virologie, Université Pierre et Marie Curie Paris 6 EA2387, AP HP, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Virol Methods 159:127-30. 2009
    ..The PCR-based analysis of HHV-6 TRS has a limited sensitivity but is highly specific, which provides the opportunity to include it in the set of molecular tools dedicated to the study of HHV-6 epidemiology...
  19. doi request reprint Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Cathia Soulie
    UMPC Université Paris 06, Paris, France
    AIDS 22:2212-4. 2008
    ..The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist...
  20. doi request reprint Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments
    Slim Fourati
    aInserm UMR S 943 bVirology Department cInfectious Disease Department dInternal Medicine Department, Pitie Salpetriere Hospital eUniversité Pierre and Marie Curie fInserm UMR S945 gAP HP hImmunology Department, Pitie Salpetriere Hospital, Paris, France
    AIDS 28:487-91. 2014
    ..Such HIV variation is a result of a combination of factors including high replication and mutation rates, recombination, and APOBEC3-host selective pressure...
  21. doi request reprint HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs
    Slim Fourati
    Université Pierre et Marie Curie Paris, 4 place Jussieu, Paris, France
    J Antimicrob Chemother 67:2323-6. 2012
    ..Precise characterization of viruses present in reservoirs in long-term pretreated patients will be a major issue to consider in the context of viral eradication. We assessed the frequency of defective viruses present in cellular reservoirs...
  22. ncbi request reprint Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 19:630-2. 2005
    ..We found no clone bearing both K65R and L74V substitutions. Moreover, the S68G and V75I mutations are not necessarily linked with K65R, and could thus have their own resistance effect...
  23. doi request reprint Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals
    Slim Fourati
    UMR 943, Groupe Hospitalier Pitie Salpetriere, Laboratoire de Virologie, Paris France
    AIDS 24:2313-21. 2010
    ..Natural variation in Vif may result in reduced efficacy against APOBEC3 proteins and in increased HIV-1 diversity. We speculated that this mechanism could facilitate viral escape from certain antiretroviral drugs...
  24. doi request reprint A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion
    Caroline Petitdemange
    Immunité et Infection, Hopital Pitie Salpetriere, INSERM UMR S 945, Paris, France
    Clin Infect Dis 57:745-55. 2013
    ..In vivo, anti-3S antibodies protect against the natural killer (NK) cell-mediated CD4 depletion that occurs without efficient viral neutralization...
  25. doi request reprint The future of integrase inhibitors of HIV-1
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France
    Curr Opin Virol 2:580-7. 2012
    ..The place of this class on HIV inhibitors and their future role in perspective of novel therapies to eliminate latent HIV reservoirs and infection for cure should also be explored...
  26. pmc CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope
    Sylvain Cardinaud
    INSERM, UMR S945, Université Pierre et Marie Curie UPMC, Paris, France
    PLoS Pathog 7:e1002049. 2011
    ..Our results strongly suggest that HIV-1 escapes CTL surveillance by introducing mutations leading to HIV ARF-epitope destruction by proteasomes...
  27. doi request reprint Variability of gB and gH genes of human herpesvirus-6 among clinical specimens
    Abla Achour
    Laboratoire de Virologie, Université Pierre et Marie Curie Paris 6 EA2387, AP HP, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Med Virol 80:1211-21. 2008
    ..These results indicate that, as in the case of HCMV, homologous recombination may contribute to the genetic variability of HHV-6...
  28. doi request reprint Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma
    Cathia Soulie
    Universite Pierre et Marie Curie Paris 6, UMR S 943 Paris, F 75013 France
    J Acquir Immune Defic Syndr 51:60-4. 2009
    ....
  29. ncbi request reprint Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR
    Thuong Nguyen Thi
    Laboratoire de Virologie, Universite Pierre et Marie Curie PARIS6, EA 2387, CERVI, Hopital Pitie Salpetriere, Paris 75013, France
    Antiviral Res 69:152-7. 2006
    ..0 and 100 microM, respectively. The real-time PCR susceptibility assay reported here is rapid, reproducible, applicable for HSV-1 as well as HSV-2, and suitable for automation...